Antev Ltd.

Bergen, Norway, July 5th, 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy CyPep-1, announces the appointment of Olav Hellebø to its Board of Directors. Mr. Hellebø brings extensive international leadership experience, both in the US and Europe, across major pharmaceutical and biotechnology companies. Previously, he was Chief Executive Officer at ReNeuron, the UK-listed biotechnology company and, prior to this, Clavis Pharma, a Norwegian oncology company. Before joining Clavis, Mr. Hellebø headed up the global immunology franchise at UCB Pharma and before that was head of UK commercial operations at Novartis. He also held a number of senior commercial roles at Schering-Plough, including leading its US commercial operations in the areas of oncology, cardiovascular and hepatitis-C representing annual sales in excess of $2 billion. He holds an MBA from the IESE Business School, Barcelona, and a Bachelor of Business Administration from Hofstra University in the US. Olav currently serves on the Board of Antev, a UK-based private biotechnology company with a focus on prostate cancer. Stein Christian Mohn, Chairman at Cytovation said: “We are very pleased to welcome Olav to our Board of Directors. We believe that his extensive and broad-ranging experience in the industry will prove invaluable for the advancement of CyPep-1 and the continuing growth of the company as we continue to make excellent progress in our ongoing clinical program both in Europe and the US.” Olav Hellebø, added: “CyPep-1 has great potential as an innovative treatment for solid tumors where there is significant unmet medical need despite recent advances in cancer treatment. I look forward to working with the talented team at Cytovation to help bring this unique therapy to patients.” *** About Cytovation Cytovation ASA is a privately held, clinical stage immune-oncology company focused on the development of CyPep-1, a first-in-class immunotherapy targeting the cell membrane of tumor cells. CyPep-1 has a unique mechanism of action, specifically eliminating cancer cells by targeting the plasma membrane, releasing neo-antigens and inhibiting the WNT/B-catenin pathway. This dual mode of action promotes an inflammatory microenvironment and induces a tumor-specific immune response by in situ vaccination. The company is a spin-off from the University of Bergen (Norway), the city where it is headquartered. For more information, please visit www.cytovation.com. Contact Information Cytovation Federico Grego, Chief Operating Officer: contact@cytovation.com MEDiSTRAVA Consulting Frazer Hall / Mark Swallow / Evelyn McCormack: cytovation@medistrava.com

Phase 3 aims to demonstrate cardiovascular benefit of Teverelix versus GnRH agonists.Up to 30% of advanced prostate cancer patients on Androgen Deprivation Therapy have pre-existing Cardiovascular Disease. Phase 3 top-line results expected in 2027. LONDON, March 08, 2023 (GLOBE NEWSWIRE) -- Antev Ltd., a late clinical-stage biotech company developing a novel gonadotrophin-releasing hormone (GnRH) antagonist, Teverelix trifluoroacetate (Teverelix), announces that the US Food & Drug Administration (FDA) has provided written guidance on the company’s proposed Phase 3 pivotal trial design. This would be the first Phase 3 trial for a specific label to treat prostate cancer in patients with increased cardiovascular risk, addressing a significant need for prostate cancer drugs with a better cardiac toxicity profile. Prostate cancer is the second most common cause of cancer death in men[1], with around 5 million men living with the disease in the US and Europe. Current treatments using GnRH agonists have been shown[2] to have between two and four times increased risk of cardiovascular events in patients with a medical history of cardiovascular disease than antagonist treatments, a conclusion supported by the American Heart Association in a 2021 scientific statement[3][4]. Prior to initiating androgen deprivation therapy (ADT), a common form of hormone therapy, an estimated 30% of men have known cardiovascular disease (CVD)[5]. Teverelix, a decapeptide, has the potential to be the first hormone therapy specifically approved to treat advanced prostate cancer patients with a history of cardiovascular disease. “We are delighted to reach this critical milestone in Antev’s journey to secure regulatory guidance to develop Teverelix in advanced prostate cancer patients with increased cardiovascular risk,” commented Amit Kohli, Chief Executive Officer of Antev. “This written acceptance by the US FDA on our proposed Phase 3 pivotal trial design provides great visibility and supports the company’s clinical plans for our innovative treatment that could combine profound castration, improved tolerability, and significantly reduced cardiovascular risk compared to GnRH agonists, which generate over US$ 3 billion in annual sales globally. Cardio-oncology is an important new therapeutic area, and Antev is leading the way to deliver improved patient and payor outcomes.” Antev’s Chief Medical Officer, Dr Steve van Os, added, “Having worked on the global development and registration of Xtandi® for late-stage prostate cancer patients, I am very satisfied with the progress we are making at Antev in developing a novel GnRH antagonist that could help the many earlier-stage prostate cancer patients with an increased cardiovascular risk. With cardiovascular diseases being now the leading cause of death in men with prostate cancer and with up to 30% of prostate cancer patients having a history of CVD, there is a clear and urgent need for safer therapies that treat prostate cancer, yet do not increase cardiovascular risk.” Antev's Scientific Adviser, Dr Neal Shore MD FACS, CMO of Surgery and Oncology at GenesisCare USA, said, “There is an unmet medical need for a new specific ‘cardio-oncology’ indication for androgen deprivation therapy which will effectively treat the patient’s cancer while not worsening cardiovascular safety. This proposed Phase 3 trial is designed to provide the level one evidence that this GnRH antagonist could be the treatment of choice for prostate cancer patients with cardiovascular risks.” Both GnRH agonists and antagonists are approved for the treatment of prostate cancer and although both bind to the same therapeutic target, the GnRH receptor in the pituitary gland, they have distinct mechanisms of action. While the GnRH agonist stimulates the GnRH receptor, leading to overexpression of Follicle Stimulating Hormone and Luteinizing Hormone, which in turn leads to an initial increase in the production of testosterone but then rapidly inhibited through a negative feedback loop, the GnRH antagonists directly suppress the production of sex hormones by competitively blocking the GnRH receptors at the pituitary gland, and thus do not create a testosterone surge. Antev’s proposed ANT-1111-04 is a global Phase 3 trial in up to 1,500 advanced prostate cancer patients with increased CV risk with a 1:1 randomization against standard of care (GnRH agonist) that aims to read out by 2027. References 1 – Bray et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), pp.394-424 2 – Studies by Margel et al. in 2019 (n=80) and Shore et al. 2020 (n=930). https://ic-os.org/wp-content/uploads/2020/04/2019-CV-morbidity-in-a-RCT-comparing-GnRH-agonist-and-GnRH-antagonist.pdf https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/32469183/ 3 – AAH Scientific Statement, published in Genomic and Precision Medicine (Vol 14, No. 3. 26 April 2021) “Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications: A Scientific Statement From the American Heart” Association https://www-ahajournals-org.libproxy1.nus.edu.sg/doi/10.1161/HCG.0000000000000082 4 – Accompanying AAH press release: https://newsroom.heart.org/news/close-monitoring-for-heart-risk-needed-if-breast-prostate-cancer-treatment-includes-hormones 5 – PCN194 Prevalence of Major Adverse Cardiac Events (MACE) in Patients with Prostate Cancer (PC) Receiving Androgen Deprivation Therapy (ADT) in the United States: https://www.valueinhealthjournal.com/article/S1098-3015(20)32587-0/fulltext For more information, please contact: Antev Limited Amit Kohli, CEO Email: amitkohli@antev.co.uk Scius CommunicationsKatja Stout +44 778 943 5990 katja@sciuscommunications.com Daniel Gooch +44 774 787 5479 daniel@sciuscommunications.com About Teverelix and GnRH antagonists Teverelix is an injectable, long-acting GnRH antagonist. In a novel and unique microcrystal formulation which can overcome the well documented safety issues associated with other GnRH antagonist candidates in the treatment of prostate cancer. With good injection site tolerance and a six-week dosing interval, Teverelix is likely to secure better patient compliance and therefore better clinical outcomes. Teverelix also has the potential to be developed for BPH (Benign Prostate Hyperplasia), AUR (Acute Urinary Retention), Endometriosis and Uterine Fibroids. About Antev Limited Antev Limited, based in London, is a late clinical-stage biopharmaceutical company, focused on the development of a robust registration-ready data package for the treatment of advanced prostate cancer in patients with high cardiovascular risk. Prostate cancer affects an estimated 1.3 million new patients annually around the globe and is the second most common cause of cancer death in men. Gonadotrophin-releasing hormone (GnRH) agonists and antagonists represent the foundation of prostate cancer treatment. The Company acquired the intellectual property rights for the decapeptide Teverelix, a novel GnRH antagonist, from LifeArc, one of the UK’s leading medical research charities. Teverelix is formulated as a teverelix TFA salt. It forms a microcrystalline suspension at the concentration used for injection, allowing a small injection volume. This very rare property allows for a highly injectable drug product that exhibits a sustained release. Antev is backed by private investors and was founded in 2013. For more details see our website and follow us on LinkedIn.

Los Angeles, USA, March 22, 2021 (GLOBE NEWSWIRE) -- Prostate Cancer Pipeline Insights: Comprehensive Analysis of Key Emerging Therapies and Pharmaceutical Companies With over 900 key pharmaceutical companies working, the Prostate cancer pipeline projects a robust and promising picture in near future, says DelveInsight DelveInsight’s ‘Prostate Cancer Pipeline Insights’ report highlights major breakthroughs happening in the domain, emerging therapies in different stages of clinical development, segmented based on MoA, RoA, molecule types, drug delivery platform, and so on. Some of the key highlights from the Prostate Cancer Drug Pipeline report: Request for Sample @ Prostate Cancer Therapeutic Assessment Prostate cancer originates from the prostate gland located in the pelvis, next to the bladder, of men. It is the second-leading cause of death due to cancers in men in the U.S. About 1 in 9 men are diagnosed with prostate cancer in their lifetime. Growths in the prostate can be benign (not cancer) or malignant (cancer). Prostate Cancer Drug Profiles Tomivosertib: Effector TherapeuticsTomivosertib (also known as eFT508) is a novel, potent and highly selective oral small molecule inhibitor of mitogen-activated protein kinase interacting kinases 1 and 2, or collectively, MNK1/2.  MNK1/2 plays a crucial role in the development of many tumors, including by controlling in a coordinated manner the expression of multiple factors that attenuate an immune response. Tomivosertib is currently in the Phase II stage of development. This Phase 2 study examines the efficacy, safety, tolerability, and pharmacokinetics (PK) of eFT508 (tomivosertib) in metastatic castration-resistant prostate cancer patients who have documented PSA progression on treatment with one of three hormone therapies – abiraterone, enzalutamide or apalutamide and for whom no curative therapy exists. The primary objective of this study is to assess the anti-tumor response to eFT508 (tomivosertib) in mCRPC. Gain more rich insights into drug profiles, trials, stages @ Prostate cancer drug pipeline Prostate Cancer Emerging Drugs Profile at a Glance Prostate Cancer Therapeutic Assessment By Product Type By Stage By Route of Administration By Molecule Type By Mechanism of Action By Targets By Stage and Molecule TypeBy Stage and Route of AdministrationBy Stage and Product Type Get a holistic view of the pipeline analysis @ Prostate Cancer Drug Pipeline and Emerging Trends Scope of the Report Coverage: GlobalKey Players: Pfizer, Myovant Biosciences, Effector Therapeutics, Mediolanum, Merck, ESSA Pharma, Sanofi, Astellas Pharma, AstraZeneca, Bayer, Janssen research & development LLC, Bristol Myers Squibb, Eli Lilly and Company, Amgen, POINT Biopharma, Hinnova Pharmaceuticals, Sophiris Bio, Ultimovacs, Foresee Pharmaceuticals, Luye Pharma Group, Abbott, AB science, Ferring pharmaceuticals, Jiangsu HengRui Medicine, Hoffmann-La Roche, Novartis, Celgene, Endocyte, Millennium Pharmaceuticals, Medivation, Veru, Progenics Pharmaceuticals, Boehringer Ingelheim, US Biotest, Antev, Elevation oncology, Abgenix, Astellas Pharma, Orion Pharma, Clovis Oncology, Exelixis, Takeda, Novus Therapeutics, Candel Therapeutics, Ipsen, MEI Pharma, Aragon Pharmaceuticals, MedImmune,  CytRx, Tmunity Therapeutics, Inovio Pharmaceuticals, Forma Therapeutics, Luye Pharma, Health Ever Bio-Tech, Advaxis, Corcept Therapeutics, and several others. Key Questions Answered Got queries? Get answers @ Prostate Cancer Emerging Therapies Table of Contents Reach out for a live demo of the report @ Prostate Cancer Pipeline Insights Related Reports Prostate Cancer MarketDelveInsight's "Prostate cancer Market Insights, Epidemiology, and Market Forecast-2030" report. Cervical Cancer MarketDelveInsight’s ‘Cervical Cancer –Market Insights, Epidemiology, and Market Forecast-2030’ report. Multiple Myeloma MarketDelveInsight’s ‘Multiple Myeloma (MM)-Market Insights, Epidemiology and Market Forecast—2030’ report. Acral Lentiginous Melanoma MarketDelveInsight's "Acral lentiginous melanoma Market Insights, Epidemiology, and Market Forecast-2030" report. Acute Lymphoblastic Leukemia MarketDelveInsight's "Acute Lymphoblastic Leukemia Market Insights, Epidemiology, and Market Forecast-2030" report. Acute Myeloid Leukemia MarketDelveInsight's "Acute Myeloid Leukemia (AML) Market Insights, Epidemiology, and Market Forecast-2030" report. Adenoid Cystic Carcinoma MarketDelveInsight's "Adenoid Cystic Carcinoma Market Insights, Epidemiology, and Market Forecast-2030" report. Adult T Cell Leukemia Lymphoma MarketDelveInsight's "Adult T-Cell Leukemia-Lymphoma - Market Insights, Epidemiology, and Market Forecast-2030" report. Advanced Liver Cancer MarketDelveInsight's "Advanced Liver Cancer - Market Insights, Epidemiology, and Market Forecast-2030" report. Advanced Melanoma MarketDelveInsight's "Advanced Melanoma - Market Insights, Epidemiology, and Market Forecast-2030" report. Advanced Pancreatic Cancer MarketDelveInsight's "Advanced Pancreatic Cancer - Market Insights, Epidemiology, and Market Forecast-2030" report. Advanced Recurrent Ovarian Cancer MarketDelveInsight's "Advanced Recurrent Ovarian Cancer - Market Insights, Epidemiology, and Market Forecast-2030" report. AIDS-Related Kaposi’s Sarcoma MarketDelveInsight's "AIDS-Related Kaposi's Sarcoma - Market Insights, Epidemiology, and Market Forecast-2030" report. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.